LINEAGE CELL THERAPEUTICS IN (LCTX) Stock Cash Flow
NYSEARCA:LCTX - NYSE Arca - US53566P1093 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -18.61M | -21.49M | -26.27M | -43.02M | -20.65M | |||
| Depreciation Amortization | 609.00K | 692.00K | 730.00K | 870.00K | 2.12M | |||
| Income Taxes - Deferred | 0.00 | -1.80M | N/A | N/A | N/A | |||
| Change In Working Capital | -8.77M | -10.80M | 18.70M | 21.10M | 1.30M | |||
| Interest Paid | 9.00K | 10.00K | 10.00K | 10.00K | 20.00K | |||
| Other non cash items | 3.67M | 4.83M | 7.90M | -2.51M | -2.52M | |||
| OPERATING CASH FLOW | -23.09M | -28.57M | 1.06M | -23.56M | -19.75M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -565.00K | -674.00K | -410.00K | -350.00K | -60.00K | |||
| Other Investing Activity | -1.74M | 47.12M | -45.75M | 10.10M | 13.10M | |||
| INVESTING CASH FLOW | -2.31M | 46.45M | -46.16M | 9.75M | 13.04M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -54.00K | -54.00K | -30.00K | -20.00K | 25.12M | |||
| Stock Issued/Repurchased | 36.10M | 6.71M | 1.79M | 38.11M | 5.13M | |||
| Other Financing Activity | -194.00K | -236.00K | -120.00K | -1.16M | -380.00K | |||
| FINANCING CASH FLOW | 35.86M | 6.42M | 1.63M | 36.93M | 29.87M | |||
| Exchange Rate Effect | -95.00K | -250.00K | -870.00K | -20.00K | -60.00K | |||
| CHANGE IN CASH | 10.36M | 24.06M | -44.34M | 23.10M | 23.10M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -23.09M | -28.57M | 1.06M | -23.56M | -19.75M | |||
| Capital Expenditure | -565.00K | -674.00K | -410.00K | -350.00K | -60.00K | |||
| FREE CASH FLOW | -23.66M | -29.24M | 650.00K | -23.91M | -19.81M | |||
All data in USD